Cerebrolysin is a mixture of peptides derived from purified porcine brain proteins that mimics the effects of natural neurotrophic factors. It is proposed to support healthspan by promoting neuronal survival, neurogenesis, and synaptic plasticity, potentially protecting against age-related cognitive decline and neurodegenerative processes. However, its efficacy is primarily studied in acute injury or disease states, not healthy aging.
Verdict
A high-risk, experimental neuro-agent with unproven benefits for healthy aging.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
High
EVIDENCE GRADE
C
MONTHLY COST
$75 - $150
Protocol
- Cycles of 5-10ml daily intramuscular injections for 10-20 days, repeated 2-4 times per year.
Flags
- A 2023 Cochrane review found no benefit on all-cause death and a statistically significant increase in non-fatal serious adverse events (vascular dementia).
- Not approved by the US FDA for any indication.
- Must be sourced from international pharmacies, raising concerns about product quality and authenticity.
- Risk of infection or injury from improper injection technique.
- Contraindicated in individuals with severe renal impairment or status epilepticus.
- Potential for allergic reactions to porcine-derived proteins.